A small HER2 reader for routine H&E slides: real-world deployment
arXiv:2610.40662v1 Announce Type: new Abstract: HER2 status decides who receives HER2-targeted therapy. Pathologists score HER2 protein by immunohistochemistry (IHC); equivocal IHC 2+ tumours, their hardest calls, wait for in situ hybridisation (ISH).